HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report released on Monday, Benzinga reports. They currently have a $82.00 price target on the stock. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q3 2023 earnings at ($1.22) EPS, Q4 2023 earnings at ($1.05) EPS, FY2023 […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective reduced by Raymond James from $156.00 to $89.00 in a research note issued to investors on Tuesday, Benzinga reports. Raymond James currently has a strong-buy rating on the stock. Other equities analysts have also issued research reports about the stock. Citigroup dropped their price target […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Robert W. Baird from $115.00 to $70.00 in a research note published on Tuesday morning, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the stock. Several other research analysts have also issued reports on APLS. The Goldman Sachs Group lifted […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) released its earnings results on Monday. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.33, MarketWatch Earnings reports. Apellis Pharmaceuticals had a negative return on equity of 221.60% and a negative net margin of 356.02%. The business had revenue of $95.00 […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $25.88 and last traded at $25.95, with a volume of 8073849 shares trading hands. The stock had previously closed at $32.02. Analysts Set New Price Targets Several equities research […]